BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Riliprubart readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Riliprubart\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06290141-11341@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270709
DTEND;VALUE=DATE:20270710
SUMMARY:Riliprubart: Phase 3 readout est. (NCT06290141)
DESCRIPTION:Riliprubart\, phase 3\, Chronic Inflammatory Demyelinating Poly
 neuropathy.\nStudy: A Study to Test the Efficacy and Safety of Riliprubart
  Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in Peopl
 e With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)\nEstimated
  primary completion: 9 July 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/riliprubart#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06290141
URL:https://assetmemo.bio/drug/riliprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06859099-11341@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20291003
DTEND;VALUE=DATE:20291004
SUMMARY:Riliprubart: Phase 3 readout est. (NCT06859099)
DESCRIPTION:Riliprubart\, phase 3.\nStudy: Long-term Safety and Efficacy St
 udy of Riliprubart in Participants With CIDP\nEstimated primary completion
 : 3 October 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ril
 iprubart#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06859099
URL:https://assetmemo.bio/drug/riliprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
